New Products, Expanding Coverage To Propel AstraZeneca In China
For the first time, new product launches start driving growth for AstraZeneca in China where a new national reimbursement scheme is likely to further expand market access to five products but that comes with a steep price cut.
You may also be interested in...
Despite a fall in overall revenue, emerging markets continued to perform strongly for AstraZeneca in the first quarter, becoming the UK group's single largest sales region globally, driven mainly by China.
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.
China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.